FHIR IG analytics| Package | hl7.fhir.uv.ebm |
| Resource Type | Evidence |
| Id | Evidence-379738.json |
| FHIR Version | R6 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: Evidence 379738
version: 5; Last updated: 2025-07-01 16:36:53+0000; Language: en
ArtifactPublicationStatus: Active
url: https://fevir.net/resources/Evidence/379738
identifier: FEvIR Object Identifier/379738
name: Evidence_for_Results_for_Hypertension_Control_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan
title: Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
citeAs:
Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan [Database Entry: FHIR Evidence Resource]. Contributors: Joanne Dehnbostel [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 379738. Revised 2025-07-01. Available at: https://fevir.net/resources/Evidence/379738. Computable resource at: https://fevir.net/resources/Evidence/379738#json.
status: Active
author: Joanne Dehnbostel:
publisher: Computable Publishing LLC
contact: support@computablepublishing.com
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
| Type | Target[x] |
| Part Of | Outcome Measure Report for QUARTET USA Trial |
description:
This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
variableDefinition
variableRole: Population
variableDefinition
variableRole: Outcome
observed: Hypertension Control at 12 weeks
statistic
statisticType: odds ratio
quantity: 2.85
numberAffected: 32
SampleSizes
Extension NumberOfParticipants KnownDataCount 62 53 attributeEstimate
type: confidence interval
level: 0.95
range: 0.94-8.59
attributeEstimate
type: p-value
quantity: 0.063
{
"resourceType": "Evidence",
"id": "379738",
"meta": {
"versionId": "5",
"lastUpdated": "2025-07-01T16:36:53.204Z"
},
"language": "en",
"text": {
"status": "extensions",
"div": "<!-- snip (see above) -->"
},
"extension": [
{
"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
"valueCodeableConcept": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
"code": "active",
"display": "Active"
}
]
}
}
],
"url": "https://fevir.net/resources/Evidence/379738",
"identifier": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "ACSN",
"display": "Accession ID"
}
],
"text": "FEvIR Object Identifier"
},
"system": "https://fevir.net/FOI",
"value": "379738",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"name": "Evidence_for_Results_for_Hypertension_Control_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan",
"title": "Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan",
"citeAs": "Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan [Database Entry: FHIR Evidence Resource]. Contributors: Joanne Dehnbostel [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 379738. Revised 2025-07-01. Available at: https://fevir.net/resources/Evidence/379738. Computable resource at: https://fevir.net/resources/Evidence/379738#json.",
"status": "active",
"author": [
{
"name": "Joanne Dehnbostel"
}
],
"publisher": "Computable Publishing LLC",
"contact": [
{
"telecom": [
{
"system": "email",
"value": "support@computablepublishing.com"
}
]
}
],
"copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"relatesTo": [
{
"type": "part-of",
"targetReference": {
"reference": "Composition/375280",
"type": "Composition",
"display": "Outcome Measure Report for QUARTET USA Trial"
}
}
],
"description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"variableDefinition": [
{
"variableRole": "population",
"observed": {
"reference": "EvidenceVariable/375183",
"type": "EvidenceVariable",
"display": "GroupAssignment: Quadpill vs. Candesartan"
}
},
{
"variableRole": "outcome",
"observed": {
"reference": "EvidenceVariable/375202",
"type": "EvidenceVariable",
"display": "Hypertension Control at 12 weeks"
}
}
],
"statistic": [
{
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000182",
"display": "odds ratio"
}
]
},
"quantity": {
"value": 2.85
},
"numberAffected": 32,
"sampleSize": {
"extension": [
{
"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/number-analyzed",
"valueUnsignedInt": 60
}
],
"numberOfParticipants": 62,
"knownDataCount": 53
},
"attributeEstimate": [
{
"type": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000196",
"display": "confidence interval"
}
]
},
"level": 0.95,
"range": {
"low": {
"value": 0.94
},
"high": {
"value": 8.59
}
}
},
{
"type": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000700",
"display": "p-value"
}
]
},
"quantity": {
"value": 0.063
}
}
]
}
]
}